# Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia

> **NCT04652349** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 279 (actual)

## Conditions studied

- Primary Hypercholesterolemia

## Interventions

- **DRUG:** HGP1910
- **DRUG:** HCP1903
- **DRUG:** HGP1909
- **DRUG:** HGP1911

## Key facts

- **NCT ID:** NCT04652349
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-06
- **Primary completion:** 2020-12-17
- **Final completion:** 2021-01-14
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2021-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04652349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04652349, "Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04652349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*